|
gptkbp:instanceOf
|
gptkb:drug
immunotherapy
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L04AA27
|
|
gptkbp:brand
|
gptkb:Gilenya
|
|
gptkbp:CASNumber
|
gptkb:162359-55-9
|
|
gptkbp:chemicalClass
|
sphingosine analog
|
|
gptkbp:contraindication
|
severe liver impairment
recent myocardial infarction
AV block
|
|
gptkbp:developer
|
gptkb:Novartis
|
|
gptkbp:discoveredBy
|
gptkb:Yoshitomi_Pharmaceuticals
|
|
gptkbp:dose
|
0.5 mg daily
|
|
gptkbp:eliminationHalfLife
|
6-9 days
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
capsule
|
|
gptkbp:genericName
|
yes
|
|
gptkbp:hasMolecularFormula
|
C19H33NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fingolimod
|
|
gptkbp:indication
|
relapsing-remitting multiple sclerosis
|
|
gptkbp:KEGGID
|
D08967
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
sphingosine-1-phosphate receptor modulator
|
|
gptkbp:MeSH_ID
|
C526747
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
307.47 g/mol
|
|
gptkbp:monitors
|
heart rate
liver function
ophthalmologic exam
|
|
gptkbp:notRecommendedFor
|
gptkb:secondary_progressive_multiple_sclerosis
primary progressive multiple sclerosis
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:patentExpired
|
2019 (US)
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:pregnancyWarning
|
teratogenic
|
|
gptkbp:PubChem_CID
|
gptkb:DB08868
gptkb:CHEMBL1176
107970
|
|
gptkbp:riskFactor
|
gptkb:cancer
gptkb:progressive_multifocal_leukoencephalopathy
infections
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:lymphopenia
gptkb:macular_edema
bradycardia
liver enzyme elevation
|
|
gptkbp:UNII
|
G9200DO99Z
|
|
gptkbp:usedFor
|
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Gilenya
|
|
gptkbp:bfsLayer
|
5
|